Trial intelligence / Profile preview

Perampanel open-label extension in refractory partial seizures

2007-006170-28Phase 3Completed

Sponsor
Eisai Co., Ltd.
Start
Jun 2008
Modality
Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, open-label trial of perampanel in epilepsy and Focal Onset Epilepsy (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of adjunctive perampanel and Efficacy variables relative to pre-randomization baseline. Started Jun 2008; status: completed.

02

Drugs

perampanel
03

Conditions

epilepsyFocal Onset Epilepsy

Beyond the preview

Go deeper on 2007-006170-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-006170-28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call